Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
The pheochromocytomas are an important cause of secondary hypertension. Although pheochromocytoma susceptibility may be associated with germline mutations in the tumor-suppressor genes VHL and NF1 and in the proto-oncogene RET, the genetic basis for most cases of nonsyndromic familial pheochromocytoma is unknown. Recently, pheochromocytoma susceptibility has been associated with germline SDHD mutations. Germline SDHD mutations were originally described in hereditary paraganglioma, a dominantly inherited disorder characterized by vascular tumors in the head and the neck, most frequently at the carotid bifurcation. The gene products of two components of succinate dehydrogenase, SDHC and SDHD, anchor the gene products of two other components, SDHA and SDHB, which form the catalytic core, to the inner-mitochondrial membrane. Although mutations in SDHC and in SDHD may cause hereditary paraganglioma, germline SDHA mutations are associated with juvenile encephalopathy, and the phenotypic consequences of SDHB mutations have not been defined. To investigate the genetic causes of pheochromocytoma, we analyzed SDHB and SDHC, in familial and in sporadic cases. Inactivating SDHB mutations were detected in two of the five kindreds with familial pheochromocytoma, two of the three kindreds with pheochromocytoma and paraganglioma susceptibility, and 1 of the 24 cases of sporadic pheochromocytoma. These findings extend the link between mitochondrial dysfunction and tumorigenesis and suggest that germline SDHB mutations are an important cause of pheochromocytoma susceptibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“germline mutations in the B, C and D subunits of SDH predispose individuals to hereditary paragangliomatosis with phaeochromocytomas (HPGL) (2 -6)”
From Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations (2005) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, a biallelic loss of succinate dehydrogenase (SDH), an alteration found in familial paragangliomas and pheochromocytomas, as well as in a subset of sporadic gastrointestinal stromal tumors, creates a build-up of succinate (Astuti et al., 2001; Janeway et al., 2011).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Astuti et al., 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The results of a clinical study further confirmed this observation by showing that patients with nonmetastatic lung cancer harbored loss-of-function mutations in SDH5128.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [128]
Experimental — accuracy not yet measuredIn the citing paper
“In cancer cells, mutations in succinate dehydrogenase subunit B (SDHB) cause susceptibility to familial pheochromocytoma99 and familial paraganglioma100 as well as gastrointestinal stromal tumors101.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [99]
In the citing paper
“In addition to the tumorigenic effects of succinate accumulation, SDH5 mutation is the key driver supporting the acquisition of epithelial–mesenchymal transition (EMT) characteristics.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [128]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 2×
“…cancers and in mouse models, results in up-regulation of angiogenic growth factors, such as vascular endothelial growth factor, secondary to a defect in ubiquitylation of the a-subunits of the HIF-1 and the HIF-2 transcription factors (Maxwell et al. 1999; Cockman et al. 2000; Ohh et al. 2000).”
BackgroundSelf-citationMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 3×
“…the iron-sulfur–protein subunit) and in both SDHC and SDHD (i.e., the genes for the integral membrane–protein subunits) are associated with neoplasia (Baysal et al. 2000; Niemann and Muller 2000; present study), autosomal recessive homozygous SDHA (i.e., the gene for the flavoprotein subunit)…”
BackgroundOhh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577 · cited 2×
“…cancers and in mouse models, results in up-regulation of angiogenic growth factors, such as vascular endothelial growth factor, secondary to a defect in ubiquitylation of the a-subunits of the HIF-1 and the HIF-2 transcription factors (Maxwell et al. 1999; Cockman et al. 2000; Ohh et al. 2000).”
BackgroundCockman, M. E., Masson, N., Mole, D. R., Jaakkola, P., Chang, G.-W., Clifford, S. C., Maher, E. R., Pugh, C. W., Ratcliffe, P. J., & Maxwell, P. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002740200 · Cited by 1,050 · cited 1×
“…cancers and in mouse models, results in up-regulation of angiogenic growth factors, such as vascular endothelial growth factor, secondary to a defect in ubiquitylation of the a-subunits of the HIF-1 and the HIF-2 transcription factors (Maxwell et al. 1999; Cockman et al. 2000; Ohh et al. 2000).”
BackgroundSelf-citationMutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875 · cited 4×
“…herein: PGL1 (MIM 168000), which results from SDHD mutations at 11q23; PGL2 (MIM 601650), which maps to 11q13, although the causative gene has not been identified (Mariman et al. 1995); and PGL3 (MIM 605373), which results from SDHC mutations at 1q21 (Baysal et al. 2000; Niemann and Muller 2000).”
BackgroundInfluentialBourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., Viegas-Péquignot, E., Munnich, A., & Rötig, A. (1995) · Nature Genetics · doi:10.1038/ng1095-144 · Cited by 730 · cited 2×
“SDHA mutations are associated with juvenile encephalopathy (Bourgeron et al. 1995), and the phenotypic consequences of SDHB mutations have not been defined.”
BackgroundHoffman, M. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1019 · Cited by 382 · cited 1×
“Interestingly, germline VHL mutations that predispose patients to pheochromocytoma do not impair HIF-1a ubiquitylation (Clifford et al. 2001; Hoffman et al. 2001).”
BackgroundClifford, S. C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1029 · Cited by 373
Gimm, O., Armanios, M. Y., Dziema, H., Neumann, H. P. H., & Eng, C. (2000) · PubMed · Cited by 274
Self-citation
Cited by
Items 101–200 of 999
King, K. S., Prodanov, T., Kantorovich, V., Fojo, T., Hewitt, J. K., Zacharin, M., Wesley, R., Lodish, M., Raygada, M., Gimenez-Roqueplo, A.-P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.6353 · Cited by 196
Nuclear genetic defects of oxidative phosphorylation
Shoubridge, E. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.20.2277 · Cited by 193
“About 10% of these tumors are hereditary and they have been associated with different cancer syndromes including von Hippel–Lindau syndrome (VHL), multiple-endocrine neoplasia type 2 (MEN2) and more rarely neurofibromatosis (Nf1) (23).”
BackgroundNeumann, H. P. H., Erlic, Z., Boedeker, C. C., Rybicki, L. A., Robledo, M., Hermsen, M., Schiavi, F., Falcioni, M., Kwok, P., Bauters, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4057 · Cited by 194
Self-citationWhole-Exome Sequencing Identifies MDH2 as a New Familial Paraganglioma Gene
Cascón, A., Comino-Méndez, I., Currás-Freixes, M., de Cubas, A. A., Contreras, L., Richter, S., Peitzsch, M., Mancikova, V., Inglada-Pérez, L., Pérez-Barrios, A., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv053 · Cited by 192
Astrom, K., Cohen, J. E., Willett-Brozick, J. E., Aston, C. E., & Baysal, B. E. (2003) · Human Genetics · doi:10.1007/s00439-003-0969-6 · Cited by 187
“These mutations include IVS1+2T→G, A13 fs, W5X, C11X, R22X, S32 fs, R38X, and Q121X (Gimm et al. 2000; Astuti et al. 2001a; Neumann et al. 2002).”
BackgroundInfluentialBalduzzi, A., Valsecchi, M. G., Uderzo, C., De Lorenzo, P., Klingebiel, T., Peters, C., Stary, J., Felice, M. S., Magyarosy, E., Conter, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66998-x · Cited by 192
Mechanisms of mitochondrial diseases
Ylikallio, E., & Suomalainen, A. (2012) · Annals of Medicine · doi:10.3109/07853890.2011.598547 · Cited by 185
Bayley, J.-P., Devilee, P., & Taschner, P. E. (2005) · BMC Medical Genetics · doi:10.1186/1471-2350-6-39 · Cited by 184
“More curious, however is the small number of SDHC mutations reported, despite inclusion of SDHC in many of the screening efforts of paraganglioma/pheochromocytoma patients [15-22].”
BackgroundLehtonen, R., Kiuru, M., Vanharanta, S., Sjöberg, J., Aaltonen, L.-M., Aittomäki, K., Arola, J., Butzow, R., Eng, C., Husgafvel-Pursiainen, K., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63091-x · Cited by 181
“pheochromocytomas.(7,9) The absence of FH mutations in pheochromocytomas may speak for differing pathways of tumorigenesis in SDH and FH deficiencies, although the number of analyzed cases is limited.”
BackgroundSelf-citationApplications of metabolomics to study cancer metabolism
Kaushik, A. K., & DeBerardinis, R. J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.009 · Cited by 179
“[51] E. Letouze, C. Martinelli, C. Loriot, N. Burnichon, N. Abermil, C. Ottolenghi, M. Janin, M. Menara, A.T. Nguyen, P. Benit, A. Buffet, C. Marcaillou, J. Bertherat, L. Amar, P. Rustin, A. De Reynies, A.P. Gimenez-Roqueplo, J. Favier, SDH mutations establish a hypermethylator phenotype in paraganglioma, Cancer Cell,…”
InfluentialOncometabolites: Unconventional triggers of oncogenic signalling cascades
Sciacovelli, M., & Frezza, C. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.025 · Cited by 178
Germline FH Mutations Presenting With Pheochromocytoma
Clark, G. R., Sciacovelli, M., Gaude, E., Walsh, D. M., Kirby, G., Simpson, M. A., Trembath, R. C., Berg, J. N., Woodward, E. R., Kinning, E., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1659 · Cited by 177
Self-citationOGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism
Dai, W., Xu, L., Yu, X., Zhang, G., Guo, H., Liu, H., Song, G., Weng, S., Dong, L., Zhu, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.12.015 · Cited by 174
The pressure rises: update on the genetics of phaeochromocytoma
Maher, E. R. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2347 · Cited by 176
Self-citationPheochromocytoma and functional paraganglioma syndrome: No longer the 10% tumor
Elder, E. E., Elder, G., & Larsson, C. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20177 · Cited by 173
“To date, susceptibility loci have been assigned to four distinct chromosomal regions; the PGL1 locus located in 11q23 [30], the PGL2 locus in 11q13 [31], the PGL3 locus in 1q21 [32], and the PGL4 locus in 1p36.”
BackgroundHypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction
Jochmanova, I., Yang, C., Zhuang, Z., & Pacak, K. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt201 · Cited by 172
Succinate inhibition of α-ketoglutarate-dependent enzymes in a yeast model of paraganglioma
Smith, E. H., Janknecht, R., & Maher, L. J. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm275 · Cited by 169
Comino-Méndez, I., de Cubas, A. A., Bernal, C., Álvarez-Escolá, C., Sánchez-Malo, C., Ramírez-Tortosa, C. L., Pedrinaci, S., Rapizzi, E., Ercolino, T., Bernini, G., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt069 · Cited by 169
An Overview of Pheochromocytoma: History, Current Concepts, Vagaries, and Diagnostic Challenges
MANGER, W. M. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.001 · Cited by 165
“Most recently, germline mutations encoding succinate dehydrogenase subunits B (SDHB) on chromosome 1p and D (SDHD) on chromosome 11q predispose to head and neck paragangliomas as well as pheochromocytomas (Baysal et al. 2000, Astuti et al. 2001, Neumann et al. 2002, Neumann et al. 2004).”
BackgroundBayley, J.-P., Launonen, V., & Tomlinson, I. P. (2008) · BMC Medical Genetics · doi:10.1186/1471-2350-9-20 · Cited by 162
“Mutations have been identified in both the gene encoding fumarate hydratase and three of the four genes encoding succinate dehydrogenase, subunits B, C and D (SDHB, -C and -D) [4-6], while no cancer-related mutations have yet been reported in SDHA.”
BackgroundTCA Cycle Defects and Cancer: When Metabolism Tunes Redox State
Cardaci, S., & Ciriolo, M. R. (2012) · International Journal of Cell Biology · doi:10.1155/2012/161837 · Cited by 161
Genetics of neuroendocrine and carcinoid tumours.
Leotlela, P. D., Jauch, A., Holtgreve-Grez, H., & Thakker, R. V. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100437 · Cited by 162
Landscape of the mitochondrial Hsp90 metabolome in tumours
Chae, Y. C., Angelin, A., Lisanti, S., Kossenkov, A. V., Speicher, K. D., Wang, H., Powers, J. F., Tischler, A. S., Pacak, K., Fliedner, S., et al. (2013) · Nature Communications · doi:10.1038/ncomms3139 · Cited by 161
Bayley, J.-P., van Minderhout, I., Weiss, M. M., Jansen, J. C., Oomen, P. H., Menko, F. H., Pasini, B., Ferrando, B., Wong, N., Alpert, L. C., et al. (2006) · BMC Medical Genetics · doi:10.1186/1471-2350-7-1 · Cited by 166
“It is now known that SDHB and SDHD, together with VHL and RET, play a major role in hereditary pheochromocytoma [15].”
BackgroundInfluentialTargeting MTHFD2 in acute myeloid leukemia
Pikman, Y., Puissant, A., Alexe, G., Furman, A., Chen, L. M., Frumm, S. M., Ross, L., Fenouille, N., Bassil, C. F., Lewis, C. A., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151574 · Cited by 159
“…chain, have been implicated in the pathogenesis of hereditary para-gangliomas (Baysal et al., 2000; Niemann and Müller, 2000), pheochromocytomas (Astuti et al., 2001), renal cell cancer (Vanharanta et al., 2004), and gastrointestinal stromal tumors (Janeway et al., 2011; Pantaleo et al., 2011).”
BackgroundXekouki, P., Szarek, E., Bullova, P., Giubellino, A., Quezado, M., Mastroyannis, S. A., Mastorakos, P., Wassif, C. A., Raygada, M., Rentia, N., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4297 · Cited by 159
Self-citationAlpha-Ketoglutarate dietary supplementation to improve health in humans
Gyanwali, B., Lim, Z. X., Soh, J., Lim, C., Guan, S. P., Goh, J., Maier, A. B., & Kennedy, B. K. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.11.003 · Cited by 173
The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase
Pollard, P., Wortham, N., & Tomlinson, I. (2003) · Annals of Medicine · doi:10.1080/07853890310018458 · Cited by 159
Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management
Maher, E. R. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2288-5 · Cited by 182
Self-citationGimenez-Roqueplo, A.-P., Caumont-Prim, A., Houzard, C., Hignette, C., Hernigou, A., Halimi, P., Niccoli, P., Leboulleux, S., Amar, L., Borson-Chazot, F., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2975 · Cited by 159
“in 2001 (10), and more recently, in 2010, in SDHAF2 (11)”
Hensen, E. F., Jordanova, E. S., van Minderhout, I. J. H. M., Hogendoorn, P. C. W., Taschner, P. E. M., van der Mey, A. G. L., Devilee, P., & Cornelisse, C. J. (2004) · Oncogene · doi:10.1038/sj.onc.1207591 · Cited by 169
“1–p35) encodes a catalytic subunit of mitochondrial complex II and has been implicated in familial paraganglioma of the head and neck as well as in familial paraganglioma of the adrenal medulla, better known as pheochromocytoma (Astuti et al., 2001).”
BackgroundBrière, J.-J., Favier, J., Bénit, P., Ghouzzi, V. E., Lorenzato, A., Rabier, D., Di Renzo, M. F., Gimenez-Roqueplo, A.-P., & Rustin, P. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi359 · Cited by 152
“This hypothesis became less attractive in the absence of detectable residual succinate-dependent redox activities from the SDHA–B subcomplex in PG samples (8), and, even less, with the report that SDHB mutations cause familial PGs as well (22).”
BackgroundSmestad, J., Erber, L., Chen, Y., & Maher, L. J. (2018) · iScience · doi:10.1016/j.isci.2018.03.012 · Cited by 151
“…pheochromocytoma (PPGL), gastrointestinal stromal tumor (GIST), renal cell carcinoma (RCC), thyroid cancer, and colon cancer (Agaimy, 2016; Astuti et al., 2001; Baysal et al., 2000; Gill et al., 2013; Nannini et al., 2014; Ni et al., 2015; Niemann and Müller, 2000; Pantaleo et al., 2015;…”
BackgroundOncometabolites‐driven tumorigenesis: From genetics to targeted therapy
Morin, A., Letouzé, É., Gimenez‐Roqueplo, A., & Favier, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.29080 · Cited by 173
van Hulsteijn, L. T., Dekkers, O. M., Hes, F. J., Smit, J. W. A., & Corssmit, E. P. M. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-101192 · Cited by 150
“The first study on SDHB-mutations in PGL was published in 2001.(6)”
BackgroundSDHAF2 (PGL2-SDH5) and Hereditary Head and Neck Paraganglioma
Kunst, H. P. M., Rutten, M., de Mönnink, J. P., Hoefsloot, L. H., Timmers, H. J. L. M., Marres, H. A. M., Jansen, J. C., Kremer, H., Bayley, J., & Cremers, C. W. R. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0420 · Cited by 163
Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma
Joshua, A. M., Ezzat, S., Asa, S. L., Evans, A. J., Broom, R. J., Freeman, M., & Knox, J. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1836 · Cited by 166
Redox control of glutamine utilization in cancer
Alberghina, L., & Gaglio, D. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.513 · Cited by 147
Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma
Burnichon, N., Buffet, A., Parfait, B., Letouzé, E., Laurendeau, I., Loriot, C., Pasmant, E., Abermil, N., Valeyrie-Allanore, L., Bertherat, J., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds374 · Cited by 148
“Neurofibromin and Sox9 IHC were performed on 18 paraffin-embedded tumor samples, including 4 samples with NF1 germline mutation, 7 samples with NF1 somatic mutation and 7 non-NF1 mutated samples (2 RET-, 1 VHL-, 1 SDHB-related tumors and 3 tumors without mutation).”
BackgroundInfluentialInborn and acquired metabolic defects in cancer
Frezza, C., Pollard, P. J., & Gottlieb, E. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0728-4 · Cited by 146
“A decade ago, heterozygous germline mutations in SDHB, SDHC, and SDHD subunits were identified as the causal tumor suppressor genes in hereditary paragangliomas and pheochromocytomas (hPGL), a rare hereditary cancer predisposition syndrome of the chromaffin tissue arising in the adrenal medulla pheochromocytoma (PCC)…”
BackgroundOncometabolites: tailoring our genes
Nowicki, S., & Gottlieb, E. (2015) · The FEBS Journal · doi:10.1111/febs.13295 · Cited by 143
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice
You, M. J., Castrillon, D. H., Bastian, B. C., O'Hagan, R. C., Bosenberg, M. W., Parsons, R., Chin, L., & DePinho, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022632099 · Cited by 144
Phaeochromocytoma, new genes and screening strategies
Gimenez‐Roqueplo, A., Lehnert, H., Mannelli, M., Neumann, H., Opocher, G., Maher, E. R., Plouin, P., & on behalf of the European Network for the Study of Adrenal Tumours (ENS@T) Pheochromocytoma Working Group (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02714.x · Cited by 145
Self-citationMalignant Head and Neck Paragangliomas in SDHB Mutation Carriers
Boedeker, C. C., Neumann, H. P. H., Maier, W., Bausch, B., Schipper, J. H., & Ridder, G. J. (2007) · Otolaryngology · doi:10.1016/j.otohns.2007.01.015 · Cited by 159
“PGL 1 is associated with mutations of the succinate dehydrogenase subunit D (SDHD) gene,(11) PGL 3 is caused by SDHC gene mutations,(12) and PGL 4 is caused by SDHB gene mutations.(13) The mitochondrial SDH complex catalyzes the oxidation of succinate to fumarate in the Krebs cycle and also feeds electrons to the resp…”
BackgroundMethodPollard, P. J., El-Bahrawy, M., Poulsom, R., Elia, G., Killick, P., Kelly, G., Hunt, T., Jeffery, R., Seedhar, P., Barwell, J., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0920 · Cited by 139
Self-citationEffects of hypoxia on tumor metabolism
Kim, J., Gao, P., & Dang, C. V. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9060-4 · Cited by 169
Lactic acidemia and mitochondrial disease
ROBINSON, B. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.05.015 · Cited by 153
“Mutations in SDHA, the Xavoprotein subunit of SDH, cause Leigh syndrome, while mutations in SDHB, SDHC and SDHD in a dominant mode are the cause of predisposition to paraganglioma and pheochromocytoma [44–48].”
BackgroundInborn errors of complex II – Unusual human mitochondrial diseases
Rustin, P., & Rötig, A. (2002) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(01)00228-6 · Cited by 135
Jiménez, C., Cote, G., Arnold, A., & Gagel, R. F. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2178 · Cited by 137
The role of complex II in disease
Hoekstra, A. S., & Bayley, J. (2012) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.11.005 · Cited by 154
“The SDHB gene is the most commonly mutated of all the SDH-related genes and SDHB mutation carriers may develop extraadrenal paragangliomas, adrenal pheochromocytomas or head and neck paragangliomas [24,25].”
BackgroundAlston, C. L., Davison, J. E., Meloni, F., van der Westhuizen, F. H., He, L., Hornig‐Do, H., Peet, A. C., Gissen, P., Goffrini, P., Ferrero, I., et al. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-101146 · Cited by 151
Mitochondria in cancer: at the crossroads of life and death
Fogg, V. C., Lanning, N. J., & MacKeigan, J. P. (2011) · 癌症:英文版 · doi:10.5732/cjc.011.10018 · Cited by 156
Clinical aspects of SDHx-related pheochromocytoma and paraganglioma
Timmers, H. J. L. M., Gimenez-Roqueplo, A.-P., Mannelli, M., & Pacak, K. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-08-0284 · Cited by 131
Mitochondria, from cell death to proliferation
Rustin, P. (2002) · Nature Genetics · doi:10.1038/ng0402-352 · Cited by 149
Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma
Muth, A., Crona, J., Gimm, O., Elmgren, A., Filipsson, K., Stenmark‐Askmalm, M., Sandstedt, J., Tengvar, M., & Tham, E. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12869 · Cited by 151
Metabolic reprogramming and its clinical implication for liver cancer
Yang, F., Hilakivi-Clarke, L. A., Shaha, A., Wang, Y., Wang, X., Deng, Y., Lai, J., & Kang, N. (2023) · Hepatology · doi:10.1097/hep.0000000000000005 · Cited by 199
Oxidative metabolism in cancer growth
Ristow, M. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000232892.43921.98 · Cited by 130
Head and Neck Paragangliomas in Von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2
Boedeker, C. C., Erlic, Z., Richard, S., Kontny, U., Gimenez‐Roqueplo, A., Cascón, A., Robledo, M., de Campos, J. M., van Nederveen, F. H., de Krijger, R. R., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0354 · Cited by 138
Self-citationParenti, G., Zampetti, B., Rapizzi, E., Ercolino, T., Giaché, V., & Mannelli, M. (2012) · Journal of Oncology · doi:10.1155/2012/872713 · Cited by 139
Young, A. L., Baysal, B. E., Deb, A., & Young, W. F. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020312 · Cited by 125
Protein-mediated assembly of succinate dehydrogenase and its cofactors
Van Vranken, J. G., Na, U., Winge, D. R., & Rutter, J. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2014.990556 · Cited by 122
“implicated in rare cases (Astuti et al., 2001; Baysal, 2000; Burnichon et al., 2010; Peczkowska et al., 2008).”
BackgroundLoriot, C., Burnichon, N., Gadessaud, N., Vescovo, L., Amar, L., Libé, R., Bertherat, J., Plouin, P.-F., Jeunemaitre, X., Gimenez-Roqueplo, A.-P., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3437 · Cited by 123
“org J Clin Endocrinol Metab, June 2012, 97(6):E954–E962”
BackgroundInfluentialMitochondrial respiratory chain complexes: apoptosis sensors mutated in cancer?
Lemarié, A., & Grimm, S. (2011) · Oncogene · doi:10.1038/onc.2011.167 · Cited by 140
“…the tumour-suppressor gene function of complex II subunits was discovered for SDHD, SDHC and SDHB (Baysal et al., 2000; Niemann and Muller, 2000; Astuti et al., 2001), two mechanisms were evoked to explain the oncogenesis process associated with complex II deficiency: (1) the establishment of a…”
BackgroundInfluentialCardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer
Karlstaedt, A., Moslehi, J. J., & de Boer, R. A. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00698-6 · Cited by 141
The role of mitochondria in the life of the nematode, Caenorhabditis elegans
Tsang, W. Y., & Lemire, B. D. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(03)00079-6 · Cited by 142
Siddiq, A., Aminova, L. R., & Ratan, R. R. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9268-7 · Cited by 129
“Interestingly, mutations in the autosomally encoded enzyme and enzyme subunits are associated with hereditary predispositions to various tumors [77-80].”
BackgroundMitochondrial Lon protease at the crossroads of oxidative stress, ageing and cancer
Pinti, M., Gibellini, L., Liu, Y., Xu, S., Lü, B., & Cossarizza, A. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2039-3 · Cited by 126
McCammon, M. T., Epstein, C. B., Przybyla-Zawislak, B., McAlister-Henn, L., & Butow, R. A. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-07-0422 · Cited by 119
“RNA binding also affects isocitrate dehydrogenase catalytic activity, suggesting a mechanism for coordinating expression of mitochondrial respiratory complexes and TCA cycle oxidative metabolism ( Anderson et al., 2000 ).”
BackgroundBayley, J., & Devilee, P. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.02.008 · Cited by 131
Vascular malformations: localized defects in vascular morphogenesis
Brouillard, P., & Vikkula, M. (2003) · Clinical Genetics · doi:10.1034/j.1399-0004.2003.00092.x · Cited by 132
Pillai, S., Gopalan, V., Smith, R. A., & Lam, A. K.-Y. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.022 · Cited by 126
Glutamate in cancers: from metabolism to signaling
Yi, H., Talmon, G., & Wang, J. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.34.20190037 · Cited by 134
SDHAF4 Promotes Mitochondrial Succinate Dehydrogenase Activity and Prevents Neurodegeneration
Vranken, J. G. V., Bricker, D. K., Dephoure, N., Gygi, S. P., Cox, J. E., Thummel, C. S., & Rutter, J. P. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.05.012 · Cited by 123
“Mutations in SDHA, SDHB, SDHC, SDHD, and SDHAF2 have also been shown to cause paragangliomas and pheochromocytomas—two classes of neuroendocrine tumors (Astuti et al., 2001; Hao et al., 2009; Fishbein and Nathanson, 2012).”
BackgroundDoyle, L. A., Nelson, D., Heinrich, M. C., Corless, C. L., & Hornick, J. L. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04300.x · Cited by 117
Benn, D. E., Croxson, M. S., Tucker, K., Bambach, C. P., Richardson, A. L., Delbridge, L., Pullan, P. T., Hammond, J., Marsh, D. J., & Robinson, B. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206300 · Cited by 108
“Occult germline SDHB mutations, one in a patient with head and neck tumours (Baysal et al., 2002), and the other in a patient with phaeochromocytoma without LOH at the SDHB locus (Astuti et al., 2001b) have been reported.”
BackgroundInfluentialMitochondrial complex II, a novel target for anti-cancer agents
Kluckova, K., Bezawork-Geleta, A., Rohlena, J., Dong, L., & Neuzil, J. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.10.015 · Cited by 104
“mutations in both familial diseases [54].”
Mitochondrial oxidative stress causes chromosomal instability of mouse embryonic fibroblasts
Samper, E., Nicholls, D. G., & Melov, S. (2003) · Aging Cell · doi:10.1046/j.1474-9728.2003.00062.x · Cited by 108
Evenepoel, L., Papathomas, T. G., Krol, N. M. G., Korpershoek, E., de Krijger, R. R., Persu, A., & Dinjens, W. N. M. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.162 · Cited by 115
Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma
Morris, M. R., Hesson, L. B., Wagner, K. J., Morgan, N. V., Astuti, D., Lees, R. D., Cooper, W. N., Lee, J., Gentle, D., MacDonald, F., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206914 · Cited by 112
“…loss, the 3p21 TSG RASSF1A is usually inactivated by epigenetic silencing (and allele loss) and only rarely by somatic mutations (Dammann et al., 2000, 2001b; Agathanggelou et al., 2001; Astuti et al., 2001a; Burbee et al., 2001; Dreijerink et al., 2001; Lo et al., 2001; Morrissey et al., 2001).”
BackgroundResultSelf-citationUpdate on pediatric pheochromocytoma
Havekes, B., Romijn, J. A., Eisenhofer, G., Adams, K. T., & Pacák, K. (2009) · Pediatric Nephrology · doi:10.1007/s00467-008-0888-9 · Cited by 116
Tseng, P., Wu, W.-H., Hu, T., Chen, C., Cheng, H.-C., Li, C., Tsai, W., Tsai, H.-J., Hsieh, M.-C., Chuang, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21361-6 · Cited by 129
Mitochondria in cancer: in the aspects of tumorigenesis and targeted therapy
Badrinath, N., & Yoo, S. Y. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy148 · Cited by 114
Multisystem manifestations of mitochondrial disorders
Donato, S. D. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5028-3 · Cited by 118
“Further investigation revealed that mutations in SDHB give rise to susceptibility to pheochromocytoma and familial paraganglioma [ 9 ], and mutations in SDHC and SDHD also cause variant forms of dominant paraganglioma [79].”
BackgroundOn the association of succinate dehydrogenase mutations with hereditary paraganglioma
Baysal, B. E. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2003.08.004 · Cited by 106
Jafri, M., & Maher, E. R. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0497 · Cited by 107
Self-citationSpiegel, R., Pines, O., Ta‐Shma, A., Burak, E., Shaag, A., Halvardson, J., Edvardson, S., Mahajna, M., Zenvirt, S., Saada, A., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.01.009 · Cited by 111
Astuti, D., Hart‐Holden, N., Latif, F., Lalloo, F. I., Black, G. C. M., Lim, C., Moran, A., Grossman, A. B., Hodgson, S. V., Freemont, A. J., et al. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01914.x · Cited by 112
“…in a single family]; one Family code Reference SDH subunit mutation No of affected individuals Number of generations involved Phenotype K1 Astuti et al. (2001b) Yes 3 3 PC & HNPGL K2 Astuti et al. (2001b) Yes 2 2 PC only K3 Astuti et al. (2001b) Yes 2 2 PC & HNPGL K4 No No 2 2 PC only K5…”
BackgroundResultSelf-citationHead and neck paragangliomas: Report of 175 patients (1989–2010)
Papaspyrou, K., Mewes, T., Rossmann, H., Fottner, C., Schneider-Rätzke, B., Bartsch, O., Schreckenberger, M., Lackner, K. J., Amedee, R. G., & Mann, W. J. (2011) · Head & Neck · doi:10.1002/hed.21790 · Cited by 107
SDH-related pheochromocytoma and paraganglioma
Kantorovich, V., King, K. S., & Pacák, K. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.04.001 · Cited by 113
Drugs and Pheochromocytoma — Don't Be Fooled by Every Elevated Metanephrine
Neary, N. M., King, K. S., & Pacák, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1101502 · Cited by 113
Guo, J., & Lemire, B. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306312200 · Cited by 103
The contribution of mitochondria to common disorders
Enns, G. M. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.009 · Cited by 113
Taïeb, D., Nölting, S., Perrier, N. D., Faßnacht, M., Carrasquillo, J. A., Grossman, A. B., Clifton-Bligh, R. J., Wanna, G. B., Schwam, Z. G., Amar, L., et al. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00926-0 · Cited by 128
Self-citationExtra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation
Pęczkowska, M., Cascón, A., Prejbisz, A., Kubaszek, A., Ćwikła, J. B., Furmanek, M. I., Erlic, Z., Eng, C., Januszewicz, A., & Neumann, H. P. H. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0726 · Cited by 108
“This patient's history, however, is suggestive of the hereditary pheochromocytoma–paraganglioma syndrome, which is associated with heterozygous gene mutations in SDHB, SDHC and SDHD , three out of the four genes encoding the subunits of the succinate dehydrogenase enzyme complex (termed mitochondrial complex II)”
BackgroundSelf-citationRattenberry, E., Vialard, L., Yeung, A. C. Y., Bair, H., McKay, K., Jafri, M., Canham, N. L. E., Cole, T. R. P., Dénes, J., Hodgson, S. V., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1319 · Cited by 110
Self-citationIdentification of Medically Actionable Secondary Findings in the 1000 Genomes
Olfson, E., Cottrell, C. E., Davidson, N. O., Gurnett, C. A., Heusel, J. W., Stitziel, N. O., Chen, L., Hartz, S. M., Nagarajan, R., Saccone, N. L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135193 · Cited by 113
“[33] showed that this variant segregated in 3 unrelated small families suffering from pheochromocytoma and paragangliomas.”
BackgroundPollard, P., Wortham, N., Barclay, E., Alam, A., Elia, G., Manek, S., Poulsom, R., & Tomlinson, I. (2005) · The Journal of Pathology · doi:10.1002/path.1686 · Cited by 100
Hoekstra, A. S., de Graaff, M. A., Briaire-de Bruijn, I. H., Ras, C., Seifar, R. M., van Minderhout, I., Cornelisse, C. J., Hogendoorn, P. C. W., Breuning, M. H., Suijker, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6091 · Cited by 99
“Germline mutations in SDHA [1], SDHB [2], SDHC [3], SDHD [4], and SDHAF2 [5] cause paraganglioma/pheochromocytoma (PGL/PCC).”
BackgroundCells Silenced for SDHB Expression Display Characteristic Features of the Tumor Phenotype
Cervera, A. M., Apostolova, N., Crespo, F. L., Mata, M., & McCreath, K. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5580 · Cited by 98
“found to be identical to SDH subunits SDHC (4) and SDHB (5).”
Succinate dehydrogenase deficiency in human
Brière, J.-J., Favier, J., Ghouzzi, V. E., Djouadi, F., Bénit, P., Gimenez‐Roqueplo, A., & Rustin, P. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5237-6 · Cited by 121
Metadata
- Authors
- Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R.
- Affiliations
- University of Birmingham (GB)
- Dana-Farber Cancer Institute (US)
- Royal Victoria Infirmary (GB)
- Queen Elizabeth Hospital (GB)
- Uppsala University (SE)
- University of Cambridge (GB)
- Corresponding author
- Maher, Eamonn R.
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-07
- Volume
- 69
- Issue
- 1
- Pages
- 49-54
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1226047
- OpenAlex
- W2025719835
- Cited by
- 1,087
- References
- 28
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 18 · 2023: 31 · 2022: 29 · 2021: 40 · 2020: 29 · 2019: 51 · 2018: 42 · 2017: 47 · 2016: 54 · 2015: 46 · 2014: 70 · 2013: 61 · 2012: 75
- FWCI
- 37.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4401 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- British Heart Foundation
- National Cancer Institute (P-30-CA-16058, P30CA016058)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- succinate dehydrogenase, SDHB, SDHC, pheochromocytoma, paraganglioma, germline mutations, mitochondrial dysfunction, sporadic pheochromocytoma, tumor suppressor, RET proto-oncogene, VHL, neurofibromatosis type 1
- MeSH terms
- Proto-Oncogene Mas, Amino Acid Sequence, Base Sequence, DNA Mutational Analysis, Female, Haplotypes, Humans, Male, Molecular Sequence Data, Mutation, Paraganglioma, Pedigree, Pheochromocytoma, Succinate Dehydrogenase, Sequence Alignment, Germ-Line Mutation, Loss of Heterozygosity, Genetic Predisposition to Disease, Mutation, Missense, Protein Subunits
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.